[HTML][HTML] Why 90% of clinical drug development fails and how to improve it?
Ninety percent of clinical drug development fails despite implementation of many successful
strategies, which raised the question whether certain aspects in target validation and drug …
strategies, which raised the question whether certain aspects in target validation and drug …
Delivering precision oncology to patients with cancer
With the increasing use of genomic profiling for diagnosis and therapy guidance in many
tumor types, precision oncology is rapidly reshaping cancer care. However, the current …
tumor types, precision oncology is rapidly reshaping cancer care. However, the current …
[HTML][HTML] Conserved pan-cancer microenvironment subtypes predict response to immunotherapy
The clinical use of molecular targeted therapy is rapidly evolving but has primarily focused
on genomic alterations. Transcriptomic analysis offers an opportunity to dissect the …
on genomic alterations. Transcriptomic analysis offers an opportunity to dissect the …
Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors
CA Milbury, J Creeden, WK Yip, DL Smith, V Pattani… - PLoS …, 2022 - journals.plos.org
FoundationOne® CDx (F1CDx) is a United States (US) Food and Drug Administration (FDA)-
approved companion diagnostic test to identify patients who may benefit from treatment in …
approved companion diagnostic test to identify patients who may benefit from treatment in …
Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 Genomes Cancer Programme
A Sosinsky, J Ambrose, W Cross, C Turnbull… - Nature Medicine, 2024 - nature.com
Abstract The Cancer Programme of the 100,000 Genomes Project was an initiative to
provide whole-genome sequencing (WGS) for patients with cancer, evaluating opportunities …
provide whole-genome sequencing (WGS) for patients with cancer, evaluating opportunities …
From target discovery to clinical drug development with human genetics
The substantial investments in human genetics and genomics made over the past three
decades were anticipated to result in many innovative therapies. Here we investigate the …
decades were anticipated to result in many innovative therapies. Here we investigate the …
Multimodal data fusion for cancer biomarker discovery with deep learning
Technological advances have made it possible to study a patient from multiple angles with
high-dimensional, high-throughput multiscale biomedical data. In oncology, massive …
high-dimensional, high-throughput multiscale biomedical data. In oncology, massive …
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
Protein tyrosine kinases of the human epidermal growth factor receptor family, including
EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung …
EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung …
Fin56-induced ferroptosis is supported by autophagy-mediated GPX4 degradation and functions synergistically with mTOR inhibition to kill bladder cancer cells
Y Sun, N Berleth, W Wu, D Schlütermann… - Cell death & …, 2021 - nature.com
Ferroptosis is a form of regulated cell death that emerges to be relevant for therapy-resistant
and dedifferentiating cancers. Although several lines of evidence suggest that ferroptosis is …
and dedifferentiating cancers. Although several lines of evidence suggest that ferroptosis is …
Therapy-induced senescence: opportunities to improve anticancer therapy
PG Prasanna, DE Citrin, J Hildesheim… - JNCI: Journal of the …, 2021 - academic.oup.com
Cellular senescence is an essential tumor suppressive mechanism that prevents the
propagation of oncogenically activated, genetically unstable, and/or damaged cells …
propagation of oncogenically activated, genetically unstable, and/or damaged cells …